Skip to main content
Clinical Trials/NCT00565994
NCT00565994
Completed
Not Applicable

A Study of Cytokine and Inflammatory Markers in Patients With Chronic Renal Failure According to Their Method of Vascular Access

University of Oklahoma1 site in 1 country60 target enrollmentJanuary 2008

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Chronic Renal Failure
Sponsor
University of Oklahoma
Enrollment
60
Locations
1
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

We hope to study components within the blood that may predict success, failure or other associated complications in relation to the type of vascular access being used.

Detailed Description

Renal failure affects more than 350,000 patients in the United States. All patients undergoing dialysis must have access to the vascular system (blood stream) for hemodialysis treatment. Methods of access include a catheter, or tube, that goes through the skin and into a large vein, a surgically created connection of a vein to an artery called an AV fistula, or a surgically created connection of a vein to artery using a graft or plastic tube. Previous research has shown considerable differences in the function and success in these types of vascular access for dialysis. Research investigators try to explain these differences and find the causes and explanations for the variations seen in vascular access. Forty patients undergoing dialysis treatment will be evaluated by analyzing serum specimens obtained during outpatient hemodialysis access. Serum will also be collected from ten pre-dialysis patients and ten normal volunteers for comparison. Pre-dialysis patients are those who have Stage 3, 4, or 5 chronic kidney disease but are not yet on dialysis and have never had any type of created vascular access. Normal subjects will have no kidney disease, autoimmune disorders, recent (\<6 months) chemotherapy treatment or corticosteroid use, or other chronic condition determined by the investigator to interfere with cytokine and inflammatory markers. The serum specimens will be analyzed for cytokine/inflammatory markers and correlated with clinical access type and other medical data and demographic information.

Registry
clinicaltrials.gov
Start Date
January 2008
End Date
September 2010
Last Updated
15 years ago
Study Type
Observational
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Male and female patients of Dr. William Jennings and Dr. Pranay Kathuria undergoing dialysis therapy as outpatients
  • Male and female patients of Dr. Pranay Kathuria who have been diagnosed with Stage 3, 4, or 5 chronic kidney disease, but who are not yet on dialysis.
  • Healthy volunteers with no kidney disease, autoimmune disorders, recent (\<6 months) chemotherapy treatment or corticosteroid use, or other chronic condition determined by the investigator to interfere with cytokine and inflammatory markers.
  • 18 to 90 years of age

Exclusion Criteria

  • under 18 years of age
  • over 90 years of age
  • prisoners
  • institutionalized patients
  • pregnant individuals
  • patients with mental illness who are not able to give informed consent

Outcomes

Primary Outcomes

Not specified

Study Sites (1)

Loading locations...

Similar Trials